Endonovo Therapeutics Provides Update on Pre-Clinical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
134
Endonovo Therapeutics Provides Update on Pre-Clinical Studies

LOS ANGELES, CA--(Marketwired - Sep 26, 2017) - Endonovo Therapeutics, Inc. ( OTCQB : ENDV ) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today provided an update on its pre-clinical studies and interim results from its pre-clinical study to assess the effectiveness of its Immunotronics™ platform in the treatment and prevention of heart failure following myocardial infarction.

Interim results from the Company's ongoing pre-clinical study to assess the effectiveness of its Immunotronics™ platform in the treatment and prevention of heart failure following myocardial infarction have demonstrated improved cardiac function and less ventricular remodeling, as evaluated using echocardiography in infarcted animals treated with the Company's non-invasive electroceutical two or three times per day for four weeks when compared to the control group. The Company expects to provide final results including histology and cytokine data in the next few weeks.

"We are very excited about these interim results," stated Endonovo CEO, Alan Collier. "We not only want to demonstrate the effectiveness of our non-invasive electroceutical, but we also want to create an easy to use device that can reduce the treatment time required to produce a meaningful effect. Our belief is that the future of medicine is electric and that our non-implantable and non-invasive electroceutical platform will be at the forefront of bioelectronic medicine," said Mr. Collier.

The Company is currently preparing to conduct additional pre-clinical studies using its newly developed electroceutical technology in the treatment of critical limb ischemia, kidney disease and Non-Alcoholic Steatohepatitis (NASH).

"We remain committed to keeping our shareholders up to date with the status of our ongoing research and development efforts and we appreciate the patience of our shareholders as we continue down this path together," concluded Mr. Collier. 

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-applications in cell therapies and non-invasive electroceuticals. Endonovo's Immunotronics™ platform is dedicated to treating patients with life-threatening inflammatory conditions in vital organs using proprietary non-invasive electroceutical devices. The Company's non-invasive platform is based on magnetically-induced electrical field pathways that target the disruption of inflammation and cell death.

The Company's Cytotronics™ platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investors: Sign Up for Email Alerts on Endonovo

Investor Relations Contact: Endonovo Therapeutics, Inc. Mr. Steven Barnes Senior Vice President of Investor Relations (800) 701-1223, Ext. 108 Sbarnes@endonovo.com www.endonovo.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 278

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 744

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 481

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 74

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 72

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 181

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 473

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 107

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 102

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 94

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading

Top 5 Most Recently Viewed Articles

Surge in Holiday Online Spending Driven by Mobile Shopping Trends

Updated Category News Views 145

The Rise of Mobile Shopping in the Holiday Season The 2024 holiday season has presented remarkable insights into consumer behavior, showcasing a notable 9% increase in online spending throughout the United States. This year's shopping frenzy, spanning from early November to the end of December, has seen consumers gravitate towards mobile devices for their purchases,...

Continue Reading
How Trump’s Tariffs Affect Your Daily Coffee Experience

Updated Category News Views 353

Exploring the Impact of Tariffs on Coffee Prices Recently, Sen. Elizabeth Warren (D-Mass.) criticized President Donald Trump during National Coffee Day, drawing attention to the rising costs of coffee that have resulted from his contentious tariff policies. While Trump expressed festive wishes associated with the day, Warren pointed out that these tariffs have caused...

Continue Reading
Replenish Nutrients: SRC Invests $15M, Aims for 5x Capacity

Updated Category News Views 49

Replenish Nutrients Aims to Change the Game When a $15 million investment surfaces in the world of regenerative agriculture, you know someone means business. SRC Agrominerals throwing cash at Replenish Nutrients could shake things up big time. Imagine an investment poised to bump Replenish's owned capacity by fivefold. It's not pocket change; it's laying down tracks for...

Continue Reading
Investing Opportunities Amid Securities Class Actions for 2025

Updated Category News Views 113

Understanding the Recent Class Action Lawsuits Law Offices of Howard G. Smith has alerted investors about ongoing class action lawsuits for several companies including Lantheus Holdings, Inc. (NASDAQ: LNTH), VF Corporation (NYSE: VFC), Fluor Corporation (NYSE: FLR), and Cytokinetics, Incorporated (NASDAQ: CYTK). Each case presents a unique opportunity for shareholders to...

Continue Reading
Silanes Market Projected to Reach $5.20 Billion by 2029

Updated Category News Views 77

Growth of the Silanes Market Towards 2029 The silanes market has been observed to be on a significant growth trajectory, with forecasts predicting an increase from USD 3.62 billion in 2024 to USD 5.20 billion by 2029. This remarkable rise is associated with a compound annual growth rate (CAGR) of 7.5% over the coming years. The driving force behind this expansion can be...

Continue Reading